A comparator trial of BPX-501 in malignant and nonmalignant pediatric patients receiving a matched unrelated donor (MUD) hematopoietic stem cell transplant (HSCT)
Latest Information Update: 15 Jul 2019
At a glance
- Drugs Rivogenlecleucel (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- 08 Jul 2019 According to a Bellicum Pharmaceuticals media release, this trial will be conducted at same time period and at the similar treatment centres where the BP-004 rivo-cel study was conducted.
- 08 Jul 2019 Results published in the Bellicum Pharmaceuticals Media Release.
- 27 Nov 2018 According to a Bellicum Pharmaceuticals media release, data from this study will be presented at the 60th American Society of Hematology (ASH) Annual Meeting.